MARKET

STIM

STIM

Neuronetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.340
-0.020
-0.46%
Closed 16:00 09/25 EDT
OPEN
4.360
PREV CLOSE
4.360
HIGH
4.410
LOW
4.150
VOLUME
166.05K
TURNOVER
--
52 WEEK HIGH
9.47
52 WEEK LOW
1.250
MARKET CAP
81.86M
P/E (TTM)
-2.3261
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Owens & Minor, Kaleido Biosciences among major healthcare gainers, MediciNova, Rite Aid leads losers pack
Gainers: Owens & Minor (OMI) +53%, Kaleido Biosciences (KLDO) +39%, LogicBio Therapeutics (LOGC) +30%,  Cellect Biotechnology (APOP) +25%, Neuronetics (STIM) +6%.Losers: MediciNova (MNOV) -20%, Rite Aid (RAD) -17%, ADiTx Therapeutics (ADTX) -12%, NanoVibronix (NAOV) -12%, Rockwell Medical (RMTI) -10%.
Seekingalpha · 1d ago
Neuronetics Unveils New Depression Data At Clinical TMS Society's Virtual Events
Neuronetics Unveils New Depression Data at Clinical TMS Society's Virtual Events MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company
Benzinga · 3d ago
GTX, GME, GNW and AIMT among midday movers
Gainers: Aimmune Therapeutics (NASDAQ:AIMT) +171%. Akcea Therapeutics (NASDAQ:AKCA) +60%. Genworth Financial (NYSE:GNW) +29%. Color Star Technology (NASDAQ
Seeking Alpha - Article · 08/31 16:53
Have Insiders Been Buying Neuronetics, Inc. (NASDAQ:STIM) Shares This Year?
Simply Wall St. · 08/31 16:04
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.
Seekingalpha · 08/31 14:58
Brainsway: Lockdowns Are Hiding Progress In The Business
Seeking Alpha - Article · 08/25 10:30
Neuronetics shares are trading higher. Not seeing any company-specific news to justify the price action.
Benzinga · 08/21 19:45
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of 19.61% and 16.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 12:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of STIM. Analyze the recent business situations of Neuronetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average STIM stock price target is 5.75 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 16.51M
% Owned: 87.56%
Shares Outstanding: 18.86M
TypeInstitutionsShares
Increased
13
438.24K
New
30
47.89K
Decreased
19
1.90M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.77%
Healthcare Equipment & Supplies
+1.78%
Key Executives
President/Chief Executive Officer/Director
Chris Thatcher
Non-Executive Chairman/Independent Director
Brian Farley
President/Chief Executive Officer/Director
Keith Sullivan
Chief Financial Officer/Vice President
Stephen Furlong
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
W. Andrew Macan
Vice President - Operations
Gregory Harper
Vice President
Yelena Tropsha
Other
Daniel Guthrie
Director
John Bakewell
Independent Director
Sheryl Conley
Independent Director
Wilfred Jaeger
Independent Director
Glenn Muir
Independent Director
Bruce Shook
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About STIM
Neuronetics, Inc. is commercial-stage medical technology company. The Company is focused on the design and development of medical devices to treat psychiatric disorders. The Company’s principal product is NeuroStar Advanced Therapy System. It is a non-invasive treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed magnetic field to induce electrical pulses for stimulating certain areas of the brain associated with mood. The system is used to treat adult patients with major depressive disorders. The Company offers its therapy systems to psychiatrist offices in the United States.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Neuronetics Inc stock information, including NASDAQ:STIM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STIM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STIM stock methods without spending real money on the virtual paper trading platform.